Preliminary PET imaging of [11C]evobrutinib in mouse models of colorectal cancer, SARS‐CoV‐2, and lung damage: Radiosynthesis via base‐aided palladium‐NiXantphos‐mediated 11C‐carbonylation

Synthesis and Preclinical Evaluation of a Novel Fluorine-18-Labeled Tracer for Positron Emission Tomography Imaging of Bruton’s Tyrosine Kinase

(2023) Kaixuan Li et al.   ACS Pharmacology & Translational Science

All Bruton’s tyrosine kinase inhibitors have similar efficacy and risks: No

(2022) Dalia L Rotstein   Multiple Sclerosis Journal

Ibrutinib Prevents Acute Lung Injury via Multi-Targeting BTK, FLT3 and EGFR in Mice

(2022) Huanan Rao et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Structure-Based Virtual Screening Reveals Ibrutinib and Zanubrutinib as Potential Repurposed Drugs against COVID-19

(2021) Satyavani Kaliamurthi et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

The Possible Role of Bruton Tyrosine Kinase Inhibitors in the Treatment of COVID-19: A Review

(2021) Mitra Rezaei et al.   CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL

Inhibition of Bruton´s tyrosine kinase as a novel therapeutic approach in multiple sclerosis

(2020) Sebastian Torke et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Radiosynthesis of a Bruton's tyrosine kinase inhibitor, [11 C]Tolebrutinib, via palladium-NiXantphos-mediated carbonylation

(2020) Kenneth Dahl et al.   JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS

Efficacy and Pharmacodynamic Modeling of the BTK Inhibitor Evobrutinib in Autoimmune Disease Models

(2019) Philipp Haselmayer et al.   JOURNAL OF IMMUNOLOGY

Discovery of Evobrutinib: An Oral, Potent, and Highly Selective, Covalent Bruton’s Tyrosine Kinase (BTK) Inhibitor for the Treatment of Immunological Diseases

(2019) Richard D. Caldwell et al.   JOURNAL OF MEDICINAL CHEMISTRY

Inhibiting Bruton’s tyrosine kinase rescues mice from lethal influenza-induced acute lung injury

(2018) Jon M. Florence et al.   AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY

The development of Bruton's tyrosine kinase (BTK) inhibitors from 2012 to 2017: A mini-review

(2018) Chengyuan Liang et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Synthesis of Diverse 11C-Labeled PET Radiotracers via Direct Incorporation of [11C]CO2

(2016) Andrew V. Mossine et al.   BIOCONJUGATE CHEMISTRY

11CO bonds made easily for positron emission tomography radiopharmaceuticals

(2016) Benjamin H. Rotstein et al.   CHEMICAL SOCIETY REVIEWS

The immune microenvironment of breast ductal carcinoma in situ

(2016) Elizabeth Thompson et al.   MODERN PATHOLOGY

Progressive changes in composition of lymphocytes in lung tissues from patients with non-small-cell lung cancer

(2016) María del Mar Valenzuela-Membrives et al.   Oncotarget

Immune and Inflammatory Cell Composition of Human Lung Cancer Stroma

(2015) G-Andre Banat et al.   PLoS One

A significant percentage of CD20-positive TILs correlates with poor prognosis in patients with primary cutaneous malignant melanoma

(2014) Miguel Martinez-Rodriguez et al.   HISTOPATHOLOGY

Sphingosine-1-phosphate receptors control B-cell migration through signaling components associated with primary immunodeficiencies, chronic lymphocytic leukemia, and multiple sclerosis

(2014) Heiko Sic et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Dual Functions of Bruton's Tyrosine Kinase and Tec Kinase during Fc  Receptor-Induced Signaling and Phagocytosis

(2014) J. Jongstra-Bilen et al.   JOURNAL OF IMMUNOLOGY

Modulating proximal cell signaling by targeting Btk ameliorates humoral autoimmunity and end-organ disease in murine lupus

(2012) Jack Hutcheson et al.   ARTHRITIS RESEARCH & THERAPY

The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells

(2011) Betty Y Chang et al.   ARTHRITIS RESEARCH & THERAPY